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Abstract
Background: With the burden of HIV and AIDS still very high, South Africa has seen an increase in commercial
traditional medicines claiming to have immune-enhancing effects. Because of lack of regulation of the traditional
medicine sector, these products have proliferated. This study aimed to evaluate the immunomodulatory effects of
uMakhonya®, a commercial traditional immune booster, using various models of normal human peripheral blood
mononuclear cells (PBMCs).
Methods: Immunosuppressed, mitogen-, and peptidoglycan (PG)-stimulated PBMCs were treated with various doses of
uMakhonya® and incubated for 24 h. The treated and control samples were analyzed for cytotoxicity, secretion of 12
different inflammatory cytokines, soluble interleukin-2 receptor (sIL-2R) levels, and nitric oxide (NO) secretion.
Results: In cytotoxicity assays, uMakhonya® induced dose-dependent cytotoxic effects in all three models, with IC50 values
of 512.08, 500, and 487.91 μg/mL for immunosuppressed, phytohaemagglutinin (PHA)-, and PG from Staphylococcus.
aureus (PG-S. aureus)-stimulated PBMCs, respectively. UMakhonya® at 100 and 10 μg/mL induced a significant (p < 0.05)
increase in the secretion of IL-1α, IL-1β, IL-6, IL-10, tumor necrosis factor alpha (TNF)-α, and granulocyte-macrophage
colony-stimulating factor (GM-CSF) in cyclosporine-, immunosuppressed, and PHA-stimulated PBMCs. In the same
samples, there was a significant increase (p < 0.05) in sIL-2R concentration, which correlated with an increase in the
secretion of inflammatory cytokines. In PBMCs stimulated with PG-S. aureus, uMakhonya® at doses of 100 and 10 μg/mL
significantly (p < 0.05) suppressed the secretion of inflammatory cytokines, especially IL-1β and TNF-α. PG-S.
aureus-stimulated PBMCs also showed a significant decrease (p < 0.05) in sIL-2R concentration when compared to control
samples. UMakhonya® insignificantly (p > 0.05) decreased NO levels in PBMCs after PG-S. aureus stimulation.
Conclusions: These results showed that uMakhonya® can induce both pro-inflammatory and anti-inflammatory effects
depending on the initial stimuli applied to immune cells.
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Background
Modernization and the technology age have brought
about a change in the operation of African traditional
medicine (ATM) and the practice of traditional healing.
Suppliers of traditional medicine include retail muthi
(herbal) shops, pharmacies, pharmaceutical manufac-
turers, herbal hawkers, and herbal wholesalers [1]. Many
of the traditional medicine manufacturers do not con-
form to Good Manufacturing Practice (GMP) standards
[2]. Commercial products based on traditional know-
ledge have not only tapped the traditional theories of
tonics but also have other added claims such as immune
enhancing properties and antimicrobial activities defined
as per the Western biomedical concepts. The HIV/AIDS
epidemic has also fueled the demand, with many pa-
tients using the so-called immune boosters that are sold
commercially [3, 4]. The increased use of herbal plants
and traditional medicine formulations necessitates devel-
opment of a mechanism for rapid evaluation of the me-
dicinal applications of these products.
Plant-derived immune tonics are widely used as a sup-
plement for maintenance of health. African tonic plants
are used to reduce fatigue, improve general health (dur-
ing or after illness), lower stress, and cleanse the blood
[5]. Based on their reported immunomodulatory effects,
plant-derived compounds have emerged as prime thera-
peutic options in recent times, leading to their rigorous
scientific examination to determine efficacy and safety
[6]. Immunomodulation is a very complex theme, related
to many diseases, with many targets for drugs, and
therefore may present with many modes of action [7].
Modulation of the immune system denotes any change
in the immune response; this may involve induction, ex-
pression, amplification, or inhibition of any phase or part
of that response [8]. Complex mixtures of traditional
medicinal herbs thought to have immunomodulatory
effects are a fixture of ATM and may include several
compounds that exhibit activity against different targets
or may even have synergistic effects [7]. Numerous in
vitro methods have been developed to evaluate the
modes of action of these potential immunomodulators
[9]. Selection of proper immune cells from suitable im-
mune organs allows for the understanding of the mode
of action of immunomodulation [10].
Novel cell receptors and signal transduction molecules
produced by immune cells have been identified and
these regulate the host response to invading microorgan-
isms. Research has been focused on finding compounds
and substances that can modulate the biologic immune
response and enhance the host’s ability to resist disease
[11]. In this study, we aimed to evaluate the immuno-
modulatory effects of uMakhonya®, a widely used herbal
immune booster in South Africa, by using various
models of human PBMCs. In an earlier study, this
traditional medicine was shown at non-cytotoxic doses is
not a chemoattractant but is able to significantly induce
chemokine secretion in LPS stimulated and unstimulated
THP-1 monocytes. The increase in chemokines secretion
may involve the activation of the NF- β signal transduc-
tion pathway [12]. We developed three different models of
PBMCs representing normal replication (PHA stimula-
tion), immunosuppression (cyclosporine-treated), and in-
fection (PG-S. aureus stimulation) of immune cells in
order to analyze uMakhonya® cytotoxicity and its effects
on inflammatory cytokines, receptor levels, and nitric
oxide (NO) secretion. The interest in such a product and
in the thousand other similar commercial products is
made relevant by their use by patients with a variety of ail-
ments, most of them related to HIV infection and AIDS.
These products, based on traditional knowledge, have be-
come synonymous with boosting the immune system to
fight opportunistic infections. [4].
Methods
Preparation of uMakhonya® formula
UMakhonya® formulation samples (Batch number:
R0101, National Pharmaceutical Product Index (NAPPI)
Code: 710345–001) were a gift from the owner of the
traditional medicine formulation, Mr. Victor Ndlovu.
This product is formulated by combining five different
plant extracts. The herbal plants are listed on the pack-
aging of the formula sold in supermarkets, and each
5 mL of uMakhonya® contains 90 mg Artemisia afra
(African wormwood, Compositae family), 8.5 mg men-
thol (produced by Lamiaceae family, mostly those of the
Mentha genus), 0.3 mL Psidium guajava liquid extract
(guava, Myrtaceae family), 0.08 mL Chondrus crispus
(Irish moss, Rhodophyceae family), and 0.06 mL Uncaria
tomentosa (cats-claw tincture, Rubiaceae family), all ex-
tracted in water. Chemical fingerprints of uMakhonya®
using gas chromatography–mass spectrometry (GC-MS)
and nuclear magnetic resonance (NMR) are provided as
additional data. The formulation is listed with the
Medicines Control Council (MCC) of South Africa and
exclusive rights are reserved. It was manufactured by
UMakhonya Natural Health Products (Pty) Ltd (Pinetown,
South Africa). At the manufacturing phase, the plants
were mixed proportionally in a 25-l tank and then ex-
tracted using tap water by boiling the tank overnight. The
extract was then cooled, filtered once with steel sift
followed by removal of finer particles using a sifting net,
and then packaged into 1- and 5-l containers.
To prepare the extract for in vitro studies, the liquid
extract was further sterile-filtered and then freeze-dried
to powder. The powdered plant material was then
reconstituted at 10 mg/mL in phosphate-buffered saline
(PBS) and this was further sterile-filtered using 0.22 μm
filters. This stock solution was then serial diluted to
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working concentrations of 1000, 500, 100, 50, and 10 μg/
mL using complete culture media (CCM). Endotoxin con-
tamination was measured using the Limulus Amebocyte
Lysate (LAL) QVL-1000TM (Lonza, USA) with a sensitiv-
ity of 0.1 endotoxin units (EU) per mL (supplementary
data, Table 1). Polymyxin B sulfate (10 μg/mL) was added
to reduce the immunostimulatory effects due to endotoxin
contamination. The recommended dose of uMakhonya®
according to the packaging is about 150 mL per day of the
liquid concentrate. This volume equated to about 800 mg
of freeze dried material [12].
Cell culture
Normal human whole blood was carefully layered onto
equal amounts of Histopaque 1077 and then centrifuged
at 600 g for 30 min at 25 °C. After centrifugation, the
buffy coat layer containing PBMCs was isolated and
washed twice in 5 mL PBS (300 g for 20 min at 25 °C).
The final pellets were re-suspended in complete culture
media at 1 × 106 cells/mL and then different models of
PBMCs were prepared according to Leung et al., [13]
with some variations. Briefly, the PBMCs were stimu-
lated with either PHA/PG-S. aureus or immunosup-
pressed with 20 μg/mL of cyclosporine for 2 h. Without
eliminating the stimulation or immunosuppressive effect
of cyclosporine, the cells were aliquoted to 6-well plates
and treated with uMakhonya® at doses ranging from
1000 μg/mL to 10 μg/mL at a ratio of 1:1. The treated
PBMCs were then incubated for 24 h at 37 °C, 5 % CO2
and 95 % humidity. At the end of the incubation period,
the cells and their supernatants were used for further
experiments.
Cell viability assay
The luminescent cell viability ATP assay kit from Pro-
mega uses recombinant luciferase to catalyze the follow-
ing reaction:
ATP + d-Luciferan +O2→Oxyluciferan + AMP+ PPi +
CO2 + Light (560 nm).
When ATP is the limiting component in the reaction,
the intensity of the emitted light is proportional to the
concentration of ATP. Based on these principles, the levels
of ATP in PBMCs stimulated with either PHA/PG-S. aur-
eus or immunosuppressed with 20 μg/mL of cyclosporine
and treated with doses of uMakhonya® were analyzed
according to manufacturer instructions. Cyclosporine
(20 μg/mL) was used as a positive control for cytotoxicity
against immune cells. Briefly, a sample (100 μL) of 24 h
treated/control cell suspension was pipetted into three dif-
ferent wells of a white opaque 96-well plate. The working
CellTiter-GloTM Reagent (cat number: G7570) was pre-
pared immediately before use and was added to the wells
with treated cells at 100 μL per well. The plate was agi-
tated on a plate shaker for 2 min at 150 g and incubated in
darkness for 10 min at room temperature. At the end of
the incubation period, the plate was loaded into the
luminometer and the relative light units (RLU) of the sam-
ples were measured. Background signals of cell culture
media and uMakhonya® doses (negative control) were
subtracted from each average read. A dose response curve
was also generated for the ATP levels using RLU versus
different concentrations of samples. The cell viability assay
was done in triplicate and repeated three times before the
follow-up assays were undertaken.
Cytokine secretion assay
The Multi-Analyte Profiler ELISArray assay kit (Qiagen,
USA) is designed to be used with supernatants from
treated cells or with serum from whole blood. For the
purpose of this research, inflammatory cytokines were
analyzed from supernatants of treated models of PBMCs
and control samples. Each kit included a 96-well plate
coated with antibodies for the various chemokines in the
microarray. Each row of the plate from 1 to 12 repre-
sented a single cytokine in the following order: IL-1α, IL-
1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-17α, interferon
gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), and
granulocyte-macrophage colony-stimulating factor (GM-
CSF). The kit had negative and positive controls. Each
sample was assayed in duplicate.
The ELISA analyses were performed according to
manufacturer instructions. Briefly, incubation of the
Table 1 Measurement of nitrite radicals as a measure of the levels of nitric oxide secretion in PBMCs stimulated with PG-S. aureus
(100 μg/mL) and treated with various doses of uMakhonya®. Treatment of stimulated PBMCs with various doses of uMakhonya® did
not effect a significant increase (p > 0.05) in NO secretion when compared to untreated, PG-S. aureus-stimulated-only and a
significant increase (p > 0.05) in NO secretion when compared to PG-stimulated plus cyclosporine-treated samples
Untreated PBMCs PG-S. aureus PG-S. aureus plus Cyclosporine PG-S. aureus plus uMakhonya® (μg/mL)
NO concentration (μM) 100 50 10
1 9.21 10.12 10.24 9.15 9.33 9.03
2 9.21 9.82 10 9.15 9.56 9.27
3 10.55 11.52 11.33 10.48 10.79 11.03
Mean ± SEM 9.66 ± 0.770 10.49 ± 0.905 10.53 ± 0.710 9.60 ± 0.770 9.90 ± 0.780 9.78 ± 1.092
SEM standard error of the mean
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samples in the 96-well plates allowed the captured anti-
bodies to bind to their specific protein of interest. Cyclo-
sporine-treated, PHA-, and PG-S. aureus-stimulated
samples treated with uMakhonya® (100 and 10 μg/mL)
and untreated control samples were analyzed. After re-
moving the unbound protein with wash buffer, biotinyl-
ated detection antibodies (50 μL) were added to the wells
to bind to the captured analyte. Following another wash,
an avidin-horseradish peroxidase conjugate (100 μL) was
added. The wells were again washed and the colorimetric
substrate solution was added, developing to a blue color
in direct proportion to the amount of protein analyte
present in the initial sample. The color development was
stopped by adding the stop solution, and the absorbance
was read at 450 nm with reference at 570 nm in a micro-
plate reader as per manufacturer instructions. Secretion of
cytokines was measured in duplicate and two independent
experiments were done.
IL-2 receptor ELISA
Analyses of human soluble IL-2 receptor (sIL-2R) levels
were carried out using the IL-2 Receptor Human ELISA
Kit from ABCAM® (England) and done according to the
provided protocol. Briefly, samples (100 μL each) of
supernatants from PBMCs treated with different doses
of uMakhonya® plus standards of known IL-2 receptor
concentrations and control samples were pipetted into
separate wells and incubated with biotinylated monoclo-
nal antibodies specific for sIL-2R (50 μL) for 3 h at room
temperature. This was followed by the addition of strep-
tavidin peroxidase enzyme (100 μL). After incubation for
30 min and washing to remove the unbound enzyme, a
substrate solution (100 μL) was added, which produced
a colored reaction. The intensity of this colored product
is directly proportional to the concentration of sIL-2R
present in the samples. The enzyme-substrate reaction
was stopped by quickly pipetting 100 μL of sulfuric acid.
The results were read immediately on a Zenyth200 spec-
trophotometer at 450 nm as the primary wavelength and
610 nm as the reference wavelength. The experiments
were done in triplicate and repeated twice per dose.
Nitric oxide secretion
The Griess reagent system from Promega (USA) was
used to measure nitrite (NO2
−), which is one of two pri-
mary, stable, and nonvolatile breakdown products of
NO. To perform the assay, 50 μL of supernatants from
peptidoglycan-stimulated and control PBMCs were plated
in triplicate on 96-well plates. The samples were left to
equilibrate to room temperature after which 50 μL of Sulf-
anilamide Solution was dispensed to all experimental sam-
ples and incubated for 10 min at room temperature away
from light. Then, 50 μL of N-1-napthylethylenediamine
dihydrochloride (NED) solution was dispensed to all
sample wells and the plate incubated for another 10 min
at room temperature, again protected from light. Absorb-
ance was then measured within 30 min on a Zenyth200
plate reader at 540 nm. Nitrite standards were included as
part of the samples and were used to draw a reference
curve. All samples and standards were done in triplicate
and the experiments were repeated twice.
Statistical analysis
Data analyses were done on Microsoft Excel to obtain
descriptive statistics. The IC50 for cytotoxicity and differ-
ent levels of significance within the different treated
groups were analyzed using one-way analysis of variance
(ANOVA) and the differences between the treated cells,
the untreated cells, and the negative control samples
were analyzed using GraphPad Prism (version 5) soft-
ware with the Tukey-Kramer multiple comparison test.




In all three models (cyclosporine-suppressed, PHA-
stimulated, and PG-S. aureus-stimulated PBMCs),
uMakhonya® induced significant (p < 0.05) cytotoxicity at
high doses (1000 to 500 μg/mL) while the effect of lower
doses (100 to 10 μg/mL) was not significant (p > 0.05).
The cytotoxicity of the high doses of uMakhonya® was
significantly greater (p < 0.05) than that of the immuno-
suppressive drug cyclosporine (Fig. 1). The IC50 values
of 512.08, 500, and 487. 91 μg/mL were recorded for
immunosuppressed, PHA-stimulated, and PG-S. aureus-
stimulated PBMCs, respectively. Further experiments
were performed with lower doses of uMakhonya® ran-
ging from 100 to 10 μg/mL, which did not show signifi-
cant cytotoxicity.
Cytokine secretion assay
In the immunosuppressive model, the effects of
uMakhonya® doses (100 and 10 μg/mL) on the secretion
of 12 inflammatory cytokines over 24 h in PBMCs pre-
treated with cyclosporine (20 μg/mL) for 2 h were ana-
lyzed. uMakhonya® significantly increased (p < 0.05) the
secretion of IL-1α, IL-1β, IL-6, and TNFα compared with
cyclosporine-only treatment. Secretion of IL-2, which is
the target of suppression by cyclosporine, did not signifi-
cantly increase after the addition of uMakhonya® (Fig. 2).
Overall, the addition of uMakhonya® stimulated the secre-
tion of inflammatory cytokines.
In the mitogen-stimulated model, the immunomodula-
tory effects of uMakhonya® were analyzed at doses 100
and 10 μg/mL on the secretion of 12 inflammatory
cytokines over 24 h in PBMCs pre-treated with PHA
(20 μg/mL) for 2 h. UMakhonya® significantly increased
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(p < 0.05) the secretion of IL-1α, IL-1β, IL-6, IL-10, TNFα,
and GM-CSF when compared to cyclosporine-only treat-
ment. IL-2 secretion was not significantly affected (p > 0.05)
by the addition of uMakhonya® compared to that observed
after PHA plus cyclosporine treatment (Fig. 3). Similar to
the immunosuppressive model, the mitogen-stimulated
model exhibited increased secretion of inflammatory
cytokines after the addition of uMakhonya®.
In the infection model, the immunomodulatory effects
of uMakhonya® were analyzed at doses of 100 and
10 μg/mL on the secretion of 12 inflammatory cytokines
over 24 h in PBMCs pre-stimulated with PG-S. aureus
(100 μg/mL) for 2 h. Secretion of IL-1β, IL-4, IL-6,
IL-12, IL-17α, IFNγ, and TNFα significantly decreased
(p < 0.05) after the addition of uMakhonya® compared to
that in PG-S. aureus-treated samples. IL-2 secretion was
not significantly affected when compared to that in con-
trol samples. Secretion of only IL-1α and GM-CSF in-
creased (p < 0.05) after the addition of uMakhonya® to
samples stimulated with PG-S. aureus (Fig. 4). Unlike
the immunosuppressive and mitogen models, overall the
addition of uMakhonya® suppressed the immunostimula-
tory effects of PG-S. aureus on the secretion of inflam-
matory cytokines.
IL-2 receptor ELISA
Soluble IL-2 receptor levels were analyzed in order to
find out whether their levels correlated with the
secretion of inflammatory cytokines in the three
different PBMC models. In immunosuppressed and
PHA-stimulated samples, the addition of uMakhonya®
significantly increased (p < 0.05) sIL-2R levels when
compared to untreated and cyclosporine-suppressed
samples (Fig. 5a-b). This correlated with the overall pro-
inflammatory effects of uMakhonya® on cytokine secre-
tion. In PG-S. aureus-stimulated samples, the addition
of uMakhonya® caused a significant decrease (p < 0.05)
in sIL-2R level when compared to samples stimulated
with PG-S. aureus only. The highest dose of
uMakhonya® (100 μg/mL) was more effective (p < 0.05)
at reducing sIL-2R in PG-S. aureus-stimulated samples
than cyclosporine (Fig. 5c). The decrease in sIL-2R levels
in PG-S. aureus-stimulated samples also correlated with
the overall anti-inflammatory effects of uMakhonya® on
cytokine secretion in the same model.
Nitric oxide secretion
Treatment of PG-S. aureus-stimulated PBMCs with various
doses of uMakhonya® did not effect a significant change
(p > 0.05) in NO secretion when compared to untreated,
PG-S. aureus-stimulated only and PG-S. aureus-stimulated
plus cyclosporine-treated samples. While stimulation of
PBMCs with PG-S. aureus caused a slight increase in NO
secretion when compared to unstimulated cells, the
addition of uMakhonya® caused a non-significant decrease
in secretion (Table 1).
Discussion
In this study, we investigated the in vitro immunomodu-
latory effects of uMakhonya®, a widely sold South
Fig. 1 The cytotoxic of effects of uMakhonya® on three different models of PBMCs, immunosuppressed, PHA-stimulated, and S. aureus peptidoglycan
(PG-S. aureus)-stimulated cells. In all three models, uMakhonya® induced significant (p< 0.05) cytotoxicity at high doses (1000 to 500 μg/mL) while the effect
of lower doses (100 to 10 μg/mL) was not significant (p> 0.05). The IC50 values of 512.08, 500, and 487. 91 μg/mL were recorded for immunosuppressed,
PHA-stimulated, and PG-S. aureus-stimulated cells, respectively. Further experiments were performed with lower doses ranging from 100 to 10 μg/mL,
which did not show significant cytotoxicity
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African immune booster product based on ATM know-
ledge. uMakhonya® immune booster, according to the
product labeling, is indicated to improve one’s immune
system. It also claims to cleanse the blood and to control
diabetes, high blood pressure, pneumonia, shingles, ul-
cers, and hemorrhoids. The results of this study showed
that uMakhonya® is significantly cytotoxic to PBMCs at
high doses (Fig. 1) with IC50 values of 512.08, 500, and
487. 91 μg/mL recorded for immunosuppressed, PHA-s-
timulated, and PG-S. aureus-stimulated PBMCs,
respectively. This is indicative of in vivo toxicity at ex-
cessively higher equivalent doses. The recommended
dose of uMakhonya® according to the packaging is about
150 mL divided into three separate doses per day. This
volume equated to about 800 mg of freeze dried mater-
ial. Although it would be difficult to extrapolate the in
vitro results to a full human physiology, this recom-
mended dosage seems minimal to cause any adverse
toxic effects. uMakhonya® at non-cytotoxic doses
ranging from 100 to 10 μg/mL were shown to stimulate
the secretion of pro-inflammatory cytokines and increase
sIL-2R levels in immunosuppressed and PHA-treated
PBMCs (Figs. 2 and 3). However, this product showed
anti-inflammatory effects by significantly decreasing in-
flammatory cytokines and sIL-2R levels in PG-S. aureus-
stimulated PBMCs (Figs. 4 and 5c). Many advances have
been made recently in the understanding of the func-
tioning of the immune system. Whether immunomodu-
lators enhance or suppress the immune response can
depend on a number of factors, including dosage as well
as route and timing of administration. This response can
also depend on the mechanism of action or site of
activity [11]. Therefore, in choosing research models to
study immunomodulators, a careful and precise process
must be followed in order to ensure that the results of
such research reflect the absolute nature and mecha-
nisms of action of the compounds in question.
uMakhonya® demonstrated that its mode of action
Fig. 2 Effects of uMakhonya® at doses of 100 and 10 μg/mL on the secretion of 12 inflammatory cytokines over 24 h in PBMCs pre-treated with
cyclosporine (20 μg/mL) for 2 h. UMakhonya® significantly increased (p < 0.05) the secretion of IL-1α, IL-1β, IL-6, and TNFα when compared with
cyclosporine-only treatment. Secretion of IL-2, which is the target of suppression by cyclosporine, did not significantly increase after the addition
of uMakhonya®
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depends on the type of stimuli applied to an in vitro im-
mune system and that these effects are dose-dependent.
Cytokines are redundant secreted proteins with
growth, differentiation, and activation functions that
regulate and determine the nature of the immune re-
sponses [14]. Therefore, altering cytokine expression and
targeting their receptors may offer therapeutic potential
[15]. The addition of uMakhonya® antagonized the im-
munosuppressive effects of cyclosporine and potentiated
the cell proliferation effects of PHA by increasing the se-
cretion of pro-inflammatory cytokines including IL-1α,
IL-1β, IL-6, IL-10, TNFα, and GM-CSF. PHA, a lectin
isolated from red kidney bean (Phaseolus vulgaris), pri-
marily stimulates T cell proliferation and it has a slight
effect on B cells. This lectin stimulate blastogenesis of T
lymphocytes by interaction with CD2 to stimulate the
production of IL-2 and IFN-γ [10]. For this study it was
observed through repeated stimulation of PBMCs that
proliferative effect of PHA normally peaks after 48 h of
stimulation. But the design of the studies necessitated
that the stimulation be standardised along with that of
immunosuppression with cyclosporine and stimulation
Fig. 3 Immunomodulatory effects of uMakhonya® at doses of 100 and 10 μg/mL on the secretion of 12 inflammatory cytokines over 24 h in
PBMCs pre-treated with PHA (20 μg/mL) for 2 h. UMakhonya® significantly increased (p < 0.05) the secretion of IL-1α, IL-1β, IL-6, IL-10, TNFα, and
GM-CSF when compared cyclosporine-only treatment. IL-2 secretion was not significantly affected (p > 0.05) by the addition of uMakhonya®
compared to that observed for PHA plus cyclosporine treatment
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with peptidoglycan. Therefore the stimulatory effects of
PHA on cytokines are not reflected in the inflammatory
cytokines secretion but the sIL-2R assay clearly demon-
strates the stimulatory effects of PHA. Immunostimu-
lants are envisaged to enhance the body’s resistance to
infection by acting through both the innate and adaptive
immune responses [9]. There was a significant correl-
ation between the increase in pro-inflammatory cytokine
secretion and the increase in sIL-2R concentration in
both immunocompromised and mitogen-stimulated
PBMCs treated with uMakhonya®. In vitro cellular acti-
vation has been observed to lead to not only the synthe-
sis of cell-associated IL-2R but also a soluble form of the
receptor, which could be found in cell-free supernatants.
The generation of sIL-2R is not a result of cell death and
the rate of release of this molecule is in proportion to its
cell surface expression [16]. The association between the
increased levels of sIL-2R and immunostimulation has
been demonstrated in various inflammatory diseases
in vivo. Siedler et al., [17] showed that patients with
Fig. 4 Immunomodulatory effects of uMakhonya® at doses of 100 and 10 μg/mL on the secretion of 12 inflammatory cytokines over 24 h in
PBMCs pre-stimulated with PG-S. aureus (100 μg/mL) for 2 h. Secretion of IL-1β, IL-4, IL-6, IL-12, IL-17α, IFNγ, and TNFα significantly decreased
(p < 0.05) after the addition of uMakhonya® compared to that in PG-S. aureus-treated samples. Secretion of IL-2 did not show a significant change
when compared to control samples. Secretion of only IL-1α and GM-CSF was increased (p < 0.05) by the addition of uMakhonya® to samples
stimulated with PG-S. aureus
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chronic liver disease (CLD) had significantly elevated
serum sIL-2R levels compared with controls and this
was associated with pro-inflammatory cytokines including
IL-2, IFNγ, or IL-6, and chemokines. The shedding of
sIL-2R may also limit the responsiveness of immune
cells to IL-2 stimuli, thereby averting any risk of an
excessive immune response which can lead to inflam-
matory disorders [18, 19]. In healthy individuals, this
immunostimulation may serve as a prophylactic, while
in immunocompromised individuals, it may act as an
Fig. 5 Soluble IL-2 receptor levels in supernatants of cyclosporine-immunosuppressed (A), PHA-stimulated (B), and PG-S. aureus-stimulated (C) PBMCs
treated with uMakhonya® doses (100 and 10 μg/mL) over 24 h. In immunosuppressed and PHA-stimulated samples, addition of uMakhonya®
significantly increased (p < 0.05) sIL-2R levels compared to untreated and cyclosporine-suppressed samples. In PG-S. aureus-stimulated samples, the
addition of uMakhonya® caused a significant decrease (p < 0.05) in sIL-2R level when compared to samples stimulated with PG-S. aureus only. The
highest dose of uMakhonya® (100 μg/mL) was more effective (p <0.05) at reducing sIL-2R in PG-S. aureus-stimulated samples than cyclosporine
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immunotherapeutic [9]. Immunomodulation using trad-
itional medicinal plants can be used as an alternative to, or
in conjunction with, conventional therapy for a variety of
diseases, especially when host defenses have to be activated
under the conditions of impaired immune response [20]. It
was also determined that this traditional medicine had
non-significant levels of endotoxin contamination at 1.8
endotoxin units (EU/mL) (additional files, Table 1). The
endotoxin levels were removed by addition of 10 μg/mL of
polymyxin B sulphate to ensure that the assessed immune
effects are directly as a result of uMakhonya®.
Pre-treatment of PBMCs with PG-S. aureus signifi-
cantly increased the secretion of pro-inflammatory
cytokines (Fig. 4). Peptidoglycan is a component of both
gram-positive and gram-negative bacterial cell walls and
is a functional lipopolysaccharide (LPS) analog. It there-
fore possesses potent pro-inflammatory properties in
vitro including the induction of IL-1 and TNFα [21].
The addition of uMakhonya® to the stimulated PBMCs
significantly decreased the concentration of pro-
inflammatory cytokines, especially IL-1β and TNFα. The
anti-inflammatory effects of uMakhonya® correlated with
the significant decrease in sIL-2R levels in supernatants
of PG-S. aureus-stimulated PBMCs (Fig. 5c). These anti-
inflammatory effects are in contrast to its intended use,
which is aimed at stimulating the immune system in
response to infections. Alternatively, these anti-
inflammatory effects may serve to control the immune
response during bacterial infections because during in-
fection, peptidoglycan recognition drives both cell-
autonomous and whole organism defense responses
[22]. In vitro studies have shown that the overall
pharmacological and therapeutic effects of medicinal
plants often do not derive from a single compound but
from several compounds generating synergistic activity
[15]. In this study, we have demonstrated that this ex-
tends to formulations of multiple medicinal plants. Such
findings have led some researchers to propose that
multi-component pharmacological agents that target
multiple sites affect the complex physiological response
more favorably than drugs that act on a single target
[15]. Herbalists have known for centuries the benefit of
using a combination of herbal remedies such as
uMakhonya®, (single extracts from medicinal plants and
combined extracts of different plants) in switching on
the body’s defense mechanisms and self-healing and pro-
tective processes [23].
There are limited studies on the immune effects of the
five medicinal plants that make up uMakhonya® but the
available data show that the majority of these medicinal
plants possess anti-inflammatory effects. Chondrus
crispus is indigenous to the Northern Hemisphere and is
the only medicinal plant extract known to induce an in-
flammatory response in vitro and in animal models.
Seaweeds are not only rich in polysaccharides, minerals,
and certain vitamins but they also contain bioactive sub-
stances such as proteins, lipids, and polyphenols. These
bioactives are known to possess potent antibacterial,
antiviral, and antifungal properties [24–26]. C. crispus
has antiviral properties and is said to be particularly use-
ful for dislodging mucus [27]. C. crispus and its resultant
component from the extract, carrageenan, are known to
be potent inflammatory agents in rodents and stimulate
mice immune cells to produce TNFα in response to bac-
terial LPS [28, 29]. Artemisia afra is used traditionally to
treat respiratory ailments and fever in combination with
Lippia javanica, suggesting its immune enhancing po-
tential. Decoctions of A. afra are taken as blood purifiers
for acne and boils. This combined with the apparent
ability to reduce stress may confer upon A. afra the sta-
tus of an immune tonic [5, 30]. Uncaria tomentosa (cat’s
claw) is a medicinal plant from the Amazon forest in
South America with a long tradition of use in the treat-
ment of a wide range of diseases including arthritis, gas-
tritis, osteoarthritis, diabetes, and cancer [31, 32]. A
study on human volunteers given Uncaria tomentosa at
350 mg daily caused a small increase in their white
blood cell counts. A follow-up clinical trial where
250–350 mg of formulated U. tomentosa was given in-
creased leukocyte count over six weeks in healthy volun-
teers [33]. Cat’s claw is a remarkably potent inhibitor of
TNFα production. The primary mechanism appears to
be immunomodulation via suppression of TNFα synthe-
sis [34]. Psidium guajava (guava) is an important food
crop and medicinal plant in tropical and subtropical
countries. Different parts of this plant are used widely in
traditional medicine practices worldwide [35, 36]. Many
pharmacological studies have demonstrated the antioxi-
dant, hepatoprotective, anti-allergic, antimicrobial, anti-
genotoxic, antiplasmodial, cytotoxic, antispasmodic,
cardioactive, antitussive, antidiabetic, anti-inflammatory,
and anti-nociceptive activities of guava, supporting its
traditional uses [37–39]. In addition to tobacco, menthol
is used in a variety of products such as foods, topical
therapeutic preparations, and oral hygiene and dental
formulations [40]. Menthol has been shown to have an-
algesic and related anti-inflammatory activities by its ef-
fect on transient receptor potential cation channel
subfamily M member 8 (TRPM8), Kappa receptor
stimulation, and inhibition of voltage gate sodium chan-
nels [41]. The complexity of active compounds produced
by the medicinal plants constituting uMakhonya® may
therefore explain the differences in response in the three
PBMCs models used in this study.
Peptidoglycan is also a potent activator of indu-
cible nitric oxide synthase (iNOS) as part of its in
vitro pro-inflammatory effects. Activation of the
iNOS by PG leads to increased production of NO
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[42, 43]. The measure of nitrite as a reflection of NO
concentration in PG-S. aureus-stimulated PBMCs showed
that treatment with uMakhonya® caused a non-significant
reduction in NO secretion when compared to other stim-
ulated cell samples (Table 1). In terms of the concentra-
tion of NO secreted by PBMCs, Jacob et al. [44] showed
that the amount of NO released from unstimulated
PBMCs cultured from control blood samples measured
using the Griess reagent system in the culture superna-
tants was 11.27 ± 2.5 μM and 8.91 ± 1.5 μM NO at 24 h
and 48 h, respectively. These values are comparable with
the results obtained in this study. NO is a physiological
mediator produced by many cells involved in immunity
and inflammation. NO is subsequently oxidized to nitrite
and nitrate, reactive nitrogen species (RNS) that mediate
most of its immunological effects [45]. Therefore the re-
duction of nitrite by uMakhonya® may reflect its antioxi-
dant effects. The oxidant scavenging properties may also
explain the anti-inflammatory effects of uMakhonya® in
PG-S. aureus-stimulated PBMCs. The five herbal medi-
cines constituting uMakhonya® have all been shown to
possess potent antioxidant properties in separate experi-
ments [33, 46–49]. Immunostimulants, as uMakhonya® is
purported to be, can be used both by healthy individuals
and persons with impaired immune systems. In healthy
individuals they are expected to act as prophylactic agents
and in individuals with impairment of the immune
response as immunotherapeutic agents [9]. A study on the
immunomodulatory effects of goldenseal and Astragalus
extracts showed that herbal medicines may function to
moderate symptoms associated with overactive pro-
inflammatory responses, with each having a distinct subset
of modulatory effects on cultured macrophages [50]. This
may provide a possible explanation for the observed pro-
and anti-inflammatory effects of by uMakhonya® doses
under different physiological stimuli. The potential uses of
immunomodulators in clinical medicine include treatment
of immunodeficiency caused by AIDS and suppression of
immune response in autoimmune disease [10].
Conclusions
This study showed that uMakhonya® is significantly
cytotoxic to PBMCs at high doses. uMakhonya® was also
shown to stimulate the secretion of pro-inflammatory
cytokines and to increase sIL-2R levels in PBMCs
immunosuppressed with cyclosporine or mitogen-
stimulated with PHA. In PG-S. aureus-stimulated PBMCs,
uMakhonya® showed anti-inflammatory effects by sup-
pressing pro-inflammatory cytokines and decreasing
sIL-2R levels in treated samples. uMakhonya® also de-
creased the amount of secreted NO in PG-S. aureus-stim-
ulated PBMCs. There is an urgent need for further studies
on the mechanisms of action of uMakhonya® and other
similar products being sold in supermarkets and
pharmacies in South Africa. Standards must be developed
to determine the types of plants that can be used in medi-
cinal products based on traditional knowledge. This is
highlighted by the use of plants in uMakhonya® that are
not indigenous to South Africa such as C. crispus and U.
tomentosa, and the use of regulated substances such as
menthol.
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